Literature DB >> 26092515

Phytopharmaceutical treatment of anxiety, depression, and dementia in the elderly: evidence from randomized, controlled clinical trials.

Siegfried Kasper1.   

Abstract

Based on subgroup analyses of randomized, controlled clinical trials, we review the efficacy of three phytopharmaceutical drugs, respectively of the corresponding active substances silexan® (WS® 1265, lavender oil) in anxiety disorders, WS® 5570 (Hypericum extract) in major depression, and EGb 761® (Ginkgo biloba extract) in Alzheimer, vascular, or mixed type dementia, in elderly patients aged ≥ 60 years. Four trials were eligible in each indication. Meta-analyses and analyses based on pooled raw data showed that the three drugs were significantly superior to placebo in the elderly subset, and that their treatment effects reflected in the main outcome measures (Hamilton Anxiety scale, Hamilton Depression scale, Neuropsychiatric Inventory) were comparable with those observed in the original trials without age restrictions. The results confirm the efficacy of the three herbal active substances in elderly patients of ≥ 60 years of age. In anxiety, depression, and dementia, they thus represent efficacious and well-tolerated alternatives to synthetic drugs.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26092515     DOI: 10.1007/s10354-015-0360-y

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  76 in total

Review 1.  Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications.

Authors:  A A Mangoni; S H D Jackson
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

Review 2.  Ginkgo biloba in Alzheimer's disease: a systematic review.

Authors:  Inger M Janssen; Sibylle Sturtz; Guido Skipka; Annette Zentner; Marcial Velasco Garrido; Marcial V Garrido; Reinhard Busse
Journal:  Wien Med Wochenschr       Date:  2010-12

Review 3.  Prevalence of dementia in the elderly in Europe.

Authors:  C Berr; J Wancata; K Ritchie
Journal:  Eur Neuropsychopharmacol       Date:  2005-08       Impact factor: 4.600

4.  Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761).

Authors:  Reham Abdel-Kader; Susanne Hauptmann; Uta Keil; Isabel Scherping; Kristina Leuner; Anne Eckert; Walter E Müller
Journal:  Pharmacol Res       Date:  2007-09-15       Impact factor: 7.658

5.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

Review 6.  Reducing fall risk in the elderly: risk factors and fall prevention, a systematic review.

Authors:  C A Pfortmueller; G Lindner; A K Exadaktylos
Journal:  Minerva Med       Date:  2014-05-27       Impact factor: 4.806

7.  EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer's disease.

Authors:  Flaubert Tchantchou; Yanan Xu; Yanjue Wu; Yves Christen; Yuan Luo
Journal:  FASEB J       Date:  2007-03-13       Impact factor: 5.191

8.  [Potentially inappropriate medication in elderly primary care patients : A retrospective, longitudinal analysis].

Authors:  T Zimmermann; H Kaduszkiewicz; H van den Bussche; G Schön; C Brettschneider; H-H König; B Wiese; H Bickel; E Mösch; M Luppa; S Riedel-Heller; J Werle; S Weyerer; A Fuchs; M Pentzek; B Hänisch; W Maier; M Scherer; F Jessen
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2013-07       Impact factor: 1.513

Review 9.  Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations.

Authors:  Francesca Borrelli; Angelo A Izzo
Journal:  AAPS J       Date:  2009-10-27       Impact factor: 4.009

Review 10.  Ginkgo biloba extract (EGb 761) in Alzheimer's disease: is there any evidence?

Authors:  Charles Ramassamy; Fanny Longpré; Yves Christen
Journal:  Curr Alzheimer Res       Date:  2007-07       Impact factor: 3.498

View more
  6 in total

Review 1.  An Overview of Systematic Reviews of Ginkgo biloba Extracts for Mild Cognitive Impairment and Dementia.

Authors:  Hong-Feng Zhang; Li-Bo Huang; Yan-Biao Zhong; Qi-Hui Zhou; Hui-Lin Wang; Guo-Qing Zheng; Yan Lin
Journal:  Front Aging Neurosci       Date:  2016-12-06       Impact factor: 5.750

2.  Similar treatment outcomes with Ginkgo biloba extract EGb 761 and donepezil in Alzheimer's dementia in very old age: A retrospective observational study.

Authors:  Michael Rapp; Martin Burkart; Thomas Kohlmann; Jens Bohlken
Journal:  Int J Clin Pharmacol Ther       Date:  2018-03       Impact factor: 1.366

3.  Antidepressant and anxiolytic activity of Lavandula officinalis aerial parts hydroalcoholic extract in scopolamine-treated rats.

Authors:  Batool Rahmati; Zahra Kiasalari; Mehrdad Roghani; Mohsen Khalili; Fariba Ansari
Journal:  Pharm Biol       Date:  2017-12       Impact factor: 3.503

Review 4.  Therapeutic effects of Silexan on somatic symptoms and physical health in patients with anxiety disorders: A meta-analysis.

Authors:  Roland von Känel; Siegfried Kasper; Guido Bondolfi; Edith Holsboer-Trachsler; Josef Hättenschwiler; Martin Hatzinger; Christian Imboden; Ellen Heitlinger; Erich Seifritz
Journal:  Brain Behav       Date:  2021-02-27       Impact factor: 2.708

5.  Identification of Anxiolytic Potential of Niranthin: In-vivo and Computational Investigations.

Authors:  Atul R Chopade; Prakash M Somade; Pratik P Somade; Suraj N Mali
Journal:  Nat Prod Bioprospect       Date:  2020-11-11

Review 6.  Potential Novel Therapies for Neurodevelopmental Diseases Targeting Oxidative Stress.

Authors:  Alexandrina S Curpan; Alina-Costina Luca; Alin Ciobica
Journal:  Oxid Med Cell Longev       Date:  2021-07-22       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.